{
    "id": "34007201-2d47-96fd-e063-6394a90a6327",
    "indications": "zelvysia indicated reduce blood phenylalanine ( phe ) levels adult pediatric patients one month age older hyperphenylalaninemia ( hpa ) due tetrahydrobiopterin- ( bh4- ) responsive phenylketonuria ( pku ) . zelvysia used conjunction phe-restricted diet .",
    "contraindications": "patients pku treated zelvysia also treated phe-restricted diet , including dietary protein phe restriction . ( 2.1 ) starting pediatric patients 1 month 6 years : recommended starting zelvysia 10 mg/kg administered orally daily . ( 2.2 ) patients 7 years older : recommended starting zelvysia 10 20 mg/kg administered orally daily . ( 2.2 ) adjustment doses zelvysia may adjusted range 5 20 mg/kg taken daily . ( 2.2 ) monitor blood phe regularly , especially pediatric patients . ( 2.2 , 5.3 ) preparation full prescribing information preparation instructions . ( 2.3 )",
    "warningsAndPrecautions": "zelvysia oral solution supplied off-white yellow powder supplied unit dose packets follows : 100 mg sapropterin dihydrochloride per packet : ndc 73289-0070-2 carton 30 unit dose packets ndc 73289-0070-1 single unit dose packet 500 mg sapropterin dihydrochloride per packet : ndc 73289-0071-2 carton 30 unit dose packets ndc 73289-0071-1 single unit dose packet storage store zelvysia oral solution 20ºc 25ºc ( 68ºf 77ºf ) ; excursions allowed 15ºc 30ºc ( 59ºf 86ºf ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "SAPROPTERIN DIHYDROCHLORIDE",
            "code": "RG277LF5B3"
        }
    ],
    "organization": "Aucta Pharmaceuticals, Inc.",
    "name": "ZELVYSIA",
    "effectiveTime": "20250430",
    "indications_original": "Zelvysia is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Zelvysia is to be used in conjunction with a Phe-restricted diet.",
    "contraindications_original": "All patients with PKU who are being treated with Zelvysia should also be treated with a Phe-restricted diet, including dietary protein and Phe restriction.  ( 2.1 ) Starting Dosage Pediatric patients 1 month to 6 years: The recommended starting dosage of Zelvysia is 10 mg/kg administered orally once daily. ( 2.2 ) Patients 7 years and older : The recommended starting dosage of Zelvysia is 10 to 20 mg/kg administered orally once daily. ( 2.2 ) Dosage Adjustment Doses of Zelvysia may be adjusted in the range of 5 to 20 mg/kg taken once daily. ( 2.2 ) Monitor blood Phe regularly, especially in pediatric patients. ( 2.2 , 5.3 ) Preparation and Administration See the full prescribing information for preparation and administration instructions. ( 2.3 )",
    "warningsAndPrecautions_original": "Zelvysia for Oral Solution\n                  \n                  Supplied as an off-white to yellow powder supplied in unit dose packets as follows:\n                  100 mg sapropterin dihydrochloride per packet:\n                  NDC 73289-0070-2    Carton of 30 unit dose packets\n                  NDC 73289-0070-1     Single unit dose packet\n                  500 mg sapropterin dihydrochloride per packet:\n                  NDC 73289-0071-2     Carton of 30 unit dose packets\n                  NDC 73289-0071-1     Single unit dose packet\n                  \n                     Storage\n                  \n                  Store Zelvysia for oral solution at 20ºC to 25ºC (68ºF to 77ºF); excursions allowed between 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "None."
}